Histological subclassification of cirrhosis
Giacomo Germani, Amar Dhillon, Lorenzo Andreana, Vincenza Calvaruso, Penelopi Manousou, Graziella Isgró, Andrew Kenneth Burroughs – 23 July 2010
Quantifying growth and transformation frequency of oncogene‐expressing mouse hepatocytes in vivo
Marxa L. Figueiredo, Kristin M. Wentworth, Eric P. Sandgren – 23 July 2010 – Gene changes can affect cancer cells in many ways, but changes that increase disease severity—by allowing cells to proliferate when they should be quiescent, by enhancing their rate of growth under growth permissive conditions, or by increasing the risk that they will accumulate additional carcinogenic alterations—must be identified so that strategies to counter their effects can be developed.
Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels
Vincent Rijckborst, Bettina E. Hansen, Yilmaz Cakaloglu, Peter Ferenci, Fehmi Tabak, Meral Akdogan, Krzysztof Simon, Ulus S. Akarca, Robert Flisiak, Elke Verhey, Anneke J. Van Vuuren, Charles A. B. Boucher, Martijn J. ter Borg, Harry L. A. Janssen – 23 July 2010 – Peginterferon alfa‐2a results in a sustained response (SR) in a minority of patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B (CHB).
High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial
Ulrich F. H. Leuschner, Birgit Lindenthal, Günter Herrmann, Joachim C. Arnold, Martin Rössle, Hans‐Jörg Cordes, Stefan Zeuzem, Jasper Hein, Thomas Berg, the NASH Study Group – 23 July 2010 – In uncontrolled clinical studies, ursodeoxycholic acid (UDCA) had a beneficial effect on nonalcoholic steatohepatitis (NASH). However, a large controlled trial using UDCA (13‐15 mg/kg/day) was unable to confirm these results. Accordingly, a randomized, placebo‐controlled study was initiated with a high dose of UDCA (23‐28 mg/kg/day).
Drug Therapy: Tenofovir
Anna S. F. Lok – 23 July 2010
Targeting heme oxygenase/adiponectin axis for chronic hepatitis C treatment
Federico Salamone, Giovanni Li Volti – 23 July 2010
Efficacy, effectiveness, and comparative effectiveness in liver disease
Hashem B. El‐Serag, Jayant Talwalkar, W. Ray Kim – 23 July 2010
Is cigarette smoking an independent risk factor or a cofactor for nonalcoholic fatty liver disease?
Cheng‐Fu Xu, Chao‐Hui Yu, Lei Xu, Min Miao, You‐Ming Li – 23 July 2010
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Kazuaki Chayama, Yusuke Nakamura, Hiromitsu Kumada – 23 July 2010 – Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG‐IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG‐IFN/ribavirin is not clear.
Hepatic iron loading in mice increases cholesterol biosynthesis
Ross M. Graham, Anita C. G. Chua, Kim W. Carter, Roheeth D. Delima, Daniel Johnstone, Carly E. Herbison, Martin J. Firth, Rebecca O'Leary, Elizabeth A. Milward, John K. Olynyk, Debbie Trinder – 23 July 2010 – Iron and cholesterol are both essential metabolites in mammalian systems, and too much or too little of either can have serious clinical consequences. In addition, both have been associated with steatosis and its progression, contributing, inter alia, to an increase in hepatic oxidative stress.